Phase II study of S-1 plus Leucovorin for metastatic pancreatic adenocarcinoma (JASPAC 03) - Phase II study of S-1 plus Leucovorin for metastatic pancreatic adenocarcinoma (JASPAC 03)

Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)0 个研究点目标入组 30 人开始时间: 2011年1月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Required to continue to take flucytosine, phenytoin, and warfarin 2) Active infections 3) High fever(over 38 degrees) 4) Severe complications (heart failure, myocardial infarction, renal failure, liver cirrhosis, ileus, interstitial lung disease, uncontrolled diabetes, cerebrovascular disorder, severe mental disorder, and so on) 5)Uncontrollable watery diarrhea or severe bowel disorder 6) Simultaneous or metachronous (within 5 years) double cancers, with the exception of intramucosal tumor curable with local therapy 7) Pregnant or lactating women or women of childbearing potential and men who want to get partner pregnant 8) Patients requiring systemic steroids medication 9) Patients who can' t receive neither iodic drug nor gadolinium because of drug allergy 10) Inadequate physical condition, as diagnosed by primary physician

发起方

Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)